AWM Investment Company Inc. Has $3.19 Million Stock Holdings in Sera Prognostics, Inc. $SERA

Key Points

• AWM Investment Company Inc. increased its stake in Sera Prognostics by 48.1% in the first quarter, now owning about 2.30% of the company, worth $3.19 million.
• CEO Zhenya Lindgardt sold 23,042 shares at $1.43 each, resulting in a 2.66% decrease in ownership, while insiders collectively sold 44,014 shares in the past three months.
• Sera Prognostics reported a quarterly loss of ($0.16) EPS, exceeding estimates, with revenue of $0.02 million against expectations of $0.05 million.

AWM Investment Company Inc. raised its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 48.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 866,837 shares of the company's stock after buying an additional 281,703 shares during the period. AWM Investment Company Inc. owned about 2.30% of Sera Prognostics worth $3,190,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Sera Prognostics during the fourth quarter worth $28,000. Sanders Morris Harris LLC increased its stake in Sera Prognostics by 4.0% during the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company's stock valued at $347,000 after purchasing an additional 3,600 shares during the last quarter. Rhumbline Advisers grew its position in shares of Sera Prognostics by 10.7% during the first quarter. Rhumbline Advisers now owns 39,970 shares of the company's stock worth $147,000 after acquiring an additional 3,869 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Sera Prognostics by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company's stock worth $499,000 after acquiring an additional 4,670 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Sera Prognostics by 55.2% during the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company's stock worth $107,000 after acquiring an additional 4,691 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 23,042 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the transaction, the chief executive officer owned 844,209 shares in the company, valued at approximately $1,207,218.87. This represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 45,587 shares of company stock valued at $74,251 in the last 90 days. Corporate insiders own 13.50% of the company's stock.

Sera Prognostics Stock Performance

Shares of NASDAQ SERA traded down $0.07 during mid-day trading on Friday, reaching $3.34. The company had a trading volume of 76,225 shares, compared to its average volume of 119,741. The stock has a fifty day moving average of $2.76 and a two-hundred day moving average of $2.89. The company has a market capitalization of $125.82 million, a price-to-earnings ratio of -3.93 and a beta of 1.00. Sera Prognostics, Inc. has a 12-month low of $1.37 and a 12-month high of $9.13.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.